Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1
36
about 6.1 years
18+
1 site in CA
What this study is about
This trial is testing a new treatment called anti-CD19 CAR-T cells to see if it's safe and can be used in people with relapsed or refractory non-Hodgkin lymphoma. The treatment involves genetically modifying T cells to target the CD19 protein on B cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive anti-CD19 CAR-T cells
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, cell therapy (Engineered T-cells that target specific cancer antigens)
infusion
Primary: Proportion of participants who experience a dose-limiting toxicity (DLT) (Dose escalation), Proportion of participants with treatment-emergent adverse events (AEs)
Secondary: Complete Response Rate, Median Overall Survival, Median Progression-free Survival (PFS), Median duration of response, Overall Response Rate (ORR), Partial Response Rate, Proportion of participants with CAR-T infusion related adverse events (Dose Escalation), Proportion of participants with delayed infusion due to study-related adverse events
Oncology